Form 4: Lifecore Biomedical Director Acquires 19,506 Shares Through RSU Grant

Katrina Houde Lovas, a Director at Lifecore Biomedical, Inc., acquired 19,506 shares of common stock through a restricted stock unit grant, increasing her total beneficial ownership to 109,412 shares.

Summary

• Katrina Houde Lovas, a Director of Lifecore Biomedical, Inc. (LFCR), acquired 19,506 shares of common stock.
• The acquisition occurred on July 15, 2025, and was made through restricted stock units (RSUs).
• These RSUs convert into common stock on a 1-for-1 basis.
• Following this transaction, Katrina Houde Lovas beneficially owns 109,412 shares of Lifecore Biomedical, Inc. common stock.
• The acquired RSUs are set to vest on the earlier of the one-year anniversary of the grant date (July 15, 2026) or the date of the company's first annual meeting of stockholders in calendar year 2026, provided that date is no less than 50 weeks from the grant date.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director is a positive indicator of insider confidence, though it is a routine compensation-related transaction rather than a major strategic announcement.

Positives

• A director's acquisition of shares, particularly through a grant of restricted stock units, aligns their interests with those of shareholders, signaling confidence in the company's future performance.
• The increase in beneficial ownership by a key insider can be viewed positively by the market.

Future Outlook

The acquired restricted stock units are subject to a vesting schedule, with vesting expected to occur on the earlier of July 15, 2026, or the date of the company's first annual meeting of stockholders in calendar year 2026, subject to a minimum 50-week holding period.

Industry Context

This Form 4 filing details an individual insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may view the director's increased ownership as a positive sign of alignment between management and shareholder interests, potentially boosting investor confidence.

Next Steps

• Vesting of the 19,506 restricted stock units on or after July 15, 2026.

Key Dates

Recommendation

Keywords

Lifecore Biomedical, LFCR, SEC Form 4, Insider Transaction, Stock Acquisition, Restricted Stock Units, Director Ownership, Beneficial Ownership